Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Pharmacology-4 PHL 425 Third Lecture By Abdelkader Ashour, Ph.D. Phone: 4677212 Email: [email protected] Pigmentation Disorders, Chloasma (Melasma) Melasma is an acquired irregular light- to dark-brown hyperpigmentation that occurs in sun-exposed areas of the skin, most often on the face and results from exposure to sunlight Clinically, It is characterized by macular hyperpigmentation of the face. Intensity (light or dark brown or even black) depends largely on the skin phototype of the patient Melasma etiological factors include: genetic background exposure to UV radiation pregnancy (melasma gravidarum, the mask of pregnancy) hormonal therapies (e.g., oral contraceptive drugs) photosensitizing drugs e.g., NSAIDs, thiazides, sulfonamides, sulfonylureas and antiepileptic medications such as diphenylhydantoin (phenytoin) The mechanism of the disease is unknown, but all cases are associated with sun exposure Chloasma, contd. It is well known that sun-exposed skin of the face contains significantly more epidermal melanocytes than the rest of the body Melasma is characterized by epidermal hyperpigmentation, possibly caused both by an increased number of melanocytes and by an increased activity of melanogenic enzymes leading to dermal changes caused by solar radiation Melasma skin has more melanin in the whole epidermis, including the stratum corneum, whereas in normal skin the melanin pigment is mostly confined to the basal layer Thus, an increased synthesis of melanosomes in the melanocytes, and increased transfer and decreased degradation of melanosomes in the keratinocytes, are suggested to be essential for the development of melasma Epidemiology, Course & Prognosis Epidemiology of chloasma in females is more than in males; about 10% of patients with melasma are men It appears in all racial types, but occurs more frequently in those persons (from Asia, the Middle East, South America) with Fitzpatrick skin phototypes IV to VI who live in areas of high UV; sun exposure deepens these hyperpigmented areas Melasma may disappear spontaneously over a period of months after delivery or after cessation of contraceptive hormones. Melasma may or may not return with each subsequent pregnancy In men, melasma rarely fades Avoiding the sun keeps the condition from worsening Management of Chloasma (melasma) Treatment depends on whether the pigmentation is epidermal or dermal. Only epidermal pigmentation responds to treatment Topical corticosteroids have been included in several clinical trials for the treatment of melasma to decrease the irritation caused by depigmenting agents The most popular depigmenting agent is hydroquinone (dihydroxybenzene; HQ) introduced for clinical use since 1961. Due to its strong depigmenting activity, HQ has been considered as a reference standard in evaluating depigmenting agents HQ exerts its effects mainly in melanocytes with active tyrosinase activity, such as epidermal hyperactivated melanocytes MOA of HQ: Considering its analogy to melanin precursors, HQ may act as an alternative substrate for tyrosinase, competing for tyrosine and dopa oxidation Following oxidation, HQ generates quinones and ROS, leading to oxidative damage to membrane lipids and alteration of membrane-bound proteins, such as tyrosinase Other putative mechanisms include: Covalent binding to histidine or interaction with coppers at the active site of tyrosinase Inhibition of RNA and DNA synthesis in melanocytes Alteration of melanosome formation and structure, and melanization extent Increase of melanosomal degradation rate within keratinocytes Destruction of melanocytes Management of Chloasma (melasma) Topical hydroquinone (3% solution and 4% cream) usually results in temporary lightening, whereas the monobenzyl ether of hydroquinone (MEH; MBEH) causes irreversible depigmentation (the clinical use is limited to obtain a generalized depigmentation in patients with diffuse vitiligo) Under no circumstances should MBEH or the other ethers of hydroquinone be used in the treatment of melasma because these drugs can lead to a permanent loss of melanocytes with the development of a disfiguring spotty leukoderma, even at sites distant from those of application (percutaneous absorption) Because of the hazard of long-term treatments with HQ (e.g., mutagenesis and tumorigenesis in animals), the use of HQ in cosmetics has been banned by the European Committee and formulations are available only by prescription of physicians and dermatologists Tretinoin (retinoic acid [RA]) inhibits tyrosinase by inhibiting the enzyme’s transcription. It also inhibits dopachrome conversion factor, with a resulting interruption of melanin synthesis. In addition, RA reduces hyperpigmentation through the induction of desquamation Concentrations ranging from 0.05% to 0.1% have been used and the associated side effects are erythema and peeling in the area of application; postinflammatory hyperpigmentation has also been reported Triple fixed combination therapy HQ 4%, RA 0.05% and fluocinolone acetonide (FA) 0.01% is more effective than either agent alone Management of Chloasma (melasma) Azelaic acid (AZA): It is a straight-chain saturated dicarboxylic acid that has been shown to be effective in the treatment of melasma AZA inhibits tyrosinase activity and may also interfere with DNA synthesis and mitochondria activity in hyperactive and abnormal melanocytes ( antiproliferative and cytotoxic effects on these melanocytes) Topical AZA (15–20%) is efficacious in the treatment of melasma AZA has been also demonstrated to be effective in the treatment of acne vulgaris It has no major side effects (irritation!) and is not able to induce depigmentation on normally pigmented skin, freckles, senile lentigines and nevi, suggesting its selective anti-proliferative and cytotoxic action on abnormal melanocytes The only problem of melasma treatment with AZA is that its therapeutical response is rather slow In order to improve this aspect, combined therapies with other agents, particularly compounds capable of accelerating desquamation have been evaluated AZA 20% plus tretinoin 0.05 or 0.1% has been shown to be more effective than AZA alone